Revised mTOR Deal With Merck Gives Ariad Time
This article was originally published in The Pink Sheet Daily
Executive Summary
Ariad gives up co-development and commercialization rights to ridaforolimus but gets $69 million to fund operations.
You may also be interested in...
FDA Panel Review Of Merck/Ariad’s Sarcoma Drug Could Hinge On Clinical Significance Of Progression-Free Survival Benefit
The Oncologic Drugs Advisory Committee will review two drugs for sarcoma indications on March 20: Merck/Ariad’s Taltorvic (ridaforolimus) and GlaxoSmithKline’s Votrient (pazopanib). With a three-week median PFS advantage in its pivotal trial, ridaforolimus could face the same questions about clinically significant benefit that led to revocation of Avastin’s metastatic breast cancer claim.
Ariad Opts-in To Co-Promote mTOR With Merck
The biotech takes advantage of the Big Pharma's financial wherewithal and regulatory/market expertise to build out its own commercial infrastructure.
Ariad Opts-in To Co-Promote mTOR With Merck
The biotech takes advantage of the Big Pharma's financial wherewithal and regulatory/market expertise to build out its own commercial infrastructure.